NYSE$SLQT

Selectquote Inc · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

SelectQuote reported Q1 2022 results with revenue up 29% year-over-year.

SelectQuote's Q1 2022 revenue increased by 29% year-over-year to $159.9 million. The company reported a net loss of $45.4 million and an adjusted EBITDA of $(44.0) million. The full-year guidance remains unchanged.

  • Consolidated revenue increased by 29% year-over-year to $159.9 million.
  • Net loss for the quarter was $45.4 million, a decrease of $46.2 million compared to the previous year.
  • Adjusted EBITDA was $(44.0) million, compared to $12.1 million in the prior year.
  • SelectRx enrollments are now over 7 times higher than at the time of acquisition.

Headline financials

Total Revenue

$160M

Previous: $124M+28.8%
EPS (adj)

-$0.28

Previous: $0.01-2900.0%
Capital Expenditures

-$7.82M

Previous: -$2.75M-184.4%
Free Cash Flow

-$53.2M

Previous: -$1.91M-2678.9%
Net Income

-$45.4M

Previous: $837K-5520.0%
Operating Income

-$52.2M

Previous: $7.27M-817.1%
Gross Profit

$67.8M

Previous: $73.1M-7.3%
Cash & Equivalents

$184M

Previous: $305M-39.9%
Total Assets

$1.39B

Previous: $1.11B+24.8%
Stock-Based Comp

$2.22M

Previous: $924K+139.7%

Revenue & EPS history

SelectQuote · Revenue · Quarterly

$160M

Q1 2022+28.8%vs Q1 2021
Beat estimate in 5 of 9 quarters(56%)
ActualEstimate

Revenue by segment

SelectQuote · $156M total across 2 segments · Q1 2022

  • Senior
    $106M+45.2%
  • Life
    $49.8M+16.4%

Forward guidance

SelectQuote began 2022 with strong results that were ahead of internal expectations, and our full year guidance remains unchanged.

Tailwinds

  • Strong results that were ahead of internal expectations.
  • Full year guidance remains unchanged.
  • Early progress of Population Health business.
  • SelectRx continues to excel, with daily enrollments now over 7 times higher than the rate of enrollment at the time of our acquisition.
  • SelectQuote is very well positioned for another year of strong revenue and EBITDA growth

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

-2.4%

Avg return

Earnings day

+1.1%

Avg return

5 days after

+2.2%

Avg return

30 days after

57%

17 / 30 earnings

Positive

+75.5%

Q2 2023

Best reaction

-49.0%

Q4 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026-8.9%+39.9%+24.3%
Q2 2026-29.0%-37.4%-47.9%
Q1 2026+0.0%-16.8%-29.3%
Q3 2025-12.1%-14.2%-15.4%
Q2 2025+30.8%+37.0%-17.4%
Q1 2025+6.9%+16.7%+46.1%
Q4 2024-49.0%-44.6%-37.6%
Q3 2024+4.8%+12.4%+13.2%
Q2 2024+6.3%+40.5%+64.0%
Q1 2024-4.3%-5.8%-3.6%
Q4 2023-16.2%-16.9%-8.8%
Q3 2023+11.1%-16.7%+16.7%
Q2 2023+75.5%+128.8%+181.1%
Q1 2023+9.5%+9.2%+17.7%
Q4 2022-30.4%-47.5%-54.9%
Q3 2022+7.5%+0.4%+20.4%
Q2 2022-48.0%-55.4%-60.1%
Q1 2022-22.3%-17.8%-36.3%
Q4 2021-44.6%-37.6%-7.2%
Q3 2020-21.5%-22.2%-23.4%
Q3 2021-21.9%-23.2%-26.6%
Q2 2020+7.7%+9.2%+7.4%
Q2 2021+7.7%+9.2%+7.4%
Q1 2020+2.7%+7.7%+20.3%
Q1 2021+7.6%+10.5%+23.0%
Q4 2018+10.9%+12.0%-2.1%
Q4 2019+10.9%+12.0%-2.1%
Q3 2019+10.9%+12.0%-2.1%
Q2 2019+10.9%+12.0%-2.1%
Q4 2020+14.2%+20.1%+0.3%
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro